Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Vægten af ​​hjerte-kar-sygdomme

24. september 2026 opdateret af: Kyla M. Lara-Breitinger, Mayo Clinic

Vægten af ​​hjerte-kar-sygdomme: en prospektiv pilotundersøgelse af overvægtige voksne med kardiovaskulær sygdom evalueret i en ny kardiometabolisk klinik

The purpose of this study is to evaluate the impact of a cardiometabolic clinic on percent body weight loss, body mass index (BMI), and visceral adiposity distribution in obese adults with cardiovascular disease (CVD) at 12 months.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

31

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Minnesota
      • Rochester, Minnesota, Forenede Stater, 55905
        • Mayo Clinic in Rochester

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients referred to the cardiometabolic clinic at Mayo Clinic Hospital in Rochester, MN will be recruited for participation.

Beskrivelse

Inclusion Criteria:

  • BMI ≥30 kg/m2
  • At least one of the following CVD: atrial fibrillation (AF), coronary artery disease (CAD), HFpEF (heart failure with preserved ejection fraction), HFrEF (heart failure with reduced ejection fraction), ACHD (adult congenital heart disease), or valvular heart disease
  • Patients evaluated in the Cardiometabolic clinic
  • Willingness to complete questionnaires/surveys
  • Ability to complete monthly self-assessments at home

Exclusion Criteria:

  • BMI <30 kg/m2
  • Pregnancy or lactating women
  • Hemodynamically unstable CVD
  • Active malignancy
  • Autoimmune or systemic inflammatory diseases
  • Severe renal or hepatic failure
  • Being considered unsafe to participate as determined by the study physician
  • Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic medications, or other medications as determined by the study NP or physician
  • Patients with active psychosis, mania, or substance use disorders

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent body weight loss
Tidsramme: 12 months

Total percent body weight loss will be reported at 12 months based on the following formula: (Starting baseline weight minus current weight) / (starting baseline weight) x 100 equals % of body weight loss.

12 months
Change in Body Mass Index (BMI)
Tidsramme: Baseline, 12 months

Body Mass Index (BMI) will be calculated using the standard formula from participants' height and weight. BMI = (Weight in Pounds / (Height in inches x Height in inches)) x 703

Baseline, 12 months
Change in visceral adiposity distribution
Tidsramme: Baseline, 12 months

Change in visceral adiposity distribution measured using dual energy X-ray absorptiometry (DEXA).

Baseline, 12 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Blood Pressure
Tidsramme: Baseline, 12 months

Measured in millimeters of mercury (mmHg)

Baseline, 12 months
Change in point of care glucose
Tidsramme: Baseline, 12 months

Change in estimated glucose value (mg/dl) obtained from point of care fingerstick testing.

Baseline, 12 months
Change in quality of diet
Tidsramme: Baseline, 12 months

Change in quality of diet will be assessed by the Mini-EAT (Eating Assessment Tool). The Mini-EAT is a 9 item questionnaire that asks subjects how often they eat different types of foods (e.g. fruits, vegetables, legumes, etc.). Subjects respond on a scale of "I do not eat it at all" to "6 or more servings per day." Higher scores on the Mini-EAT represent a better quality of diet.

Baseline, 12 months
Change in psychosocial distress as measured by Screening Tool for Psychological Distress (STOP-D)
Tidsramme: Baseline, 12 months

Psychosocial distress will be measured by the STOP-D survey. The STOP-D survey asks subjects to rate how often over the last 2 weeks they have felt depressed, anxious, stressed, angry, or lacking social support on a scale of 0-Not at all to 9-Severely. Each item is scored separately without a summed score for overall distress. Higher individual scores on the STOP-D items represent worse psychosocial distress.

Baseline, 12 months
Change in psychosocial distress as measured by Impact of Event Scale-Revised (IES-R)
Tidsramme: Baseline, 12 months

Psychosocial distress will be measured by the IES-R. The IES-R is a questionnaire which asks subjects to rate how distressed or bothered during the past seven days they have been by difficulties that people sometimes have after stressful life events. Responses can range from 0-Not at all to 4-Extremely. Items on the questionnaire are grouped into 3 subscales: Intrusion, Avoidance, and Hyperarousal with scores on each subscale being the mean item response of all items in that group, thus scores for each subscale also range from 0 to 4. Higher scores are indicative of more psychosocial distress following the specific life event of focus.

Baseline, 12 months
Change in psychosocial distress as measured by Adverse Childhood Experience (ACE) Questionnaire
Tidsramme: Baseline, 12 months

Psychosocial distress will be measured by the ACE Questionnaire. The ACE Questionnaire asks subjects various questions regarding life experiences from the first 18 years of life that may be considered adverse experiences (e.g. parental abuse, neglect, parental divorce, etc.). Subjects answer each question with a yes or no selection. The more questions answered yes represents worse psychosocial distress.

Baseline, 12 months
Change in functional aerobic capacity (VO2 Max)
Tidsramme: Baseline, 12 months

VO2 Max is measured as milliliters of oxygen per kilogram of body weight per minute (ml/kg/min) during cardiopulmonary exercise test

Baseline, 12 months
Change in artificial intelligence electrocardiogram (AI-ECG) age
Tidsramme: Baseline, 12 months

AI-ECG age is the subject's predicted age based on artificial intelligence analysis of electrocardiograms (ECGs).

Baseline, 12 months
Change in E/e'
Tidsramme: Baseline, 12 months

E/e' will be measured using transthoracic echocardiography (TTE). It is defined as the ratio of peak early diastolic mitral inflow velocity (E) and peak early diastolic mitral annular velocity (e') and will be used to assess left ventricular diastolic function.

Baseline, 12 months
Change in Peak Tricuspid Regurgitation (TR) Velocity
Tidsramme: Baseline, 12 months

Peak TR Velocity (m/s) will be measured using transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in Right Atrial (RA) Pressure
Tidsramme: Baseline, 12 months

RA pressure (mm Hg) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in Left Atrial (LA) volume index
Tidsramme: Baseline, 12 months

LA volume index (ml/m^2) will be measured by transthoracic echocardiography (TTE) to assess left ventricular diastolic function.

Baseline, 12 months
Change in physical activity
Tidsramme: Baseline, 12 months

Average number of steps a subject takes daily as collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in heart rate with detection of arrhythmia
Tidsramme: Baseline, 12 months

Average number of arrhythmias identified by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in cardio fitness
Tidsramme: Baseline, 12 months

Fitness level reported as high/above average/below average/low as collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in six-minute walk test
Tidsramme: Baseline, 12 months

Measurement (meters) of distance a person can walk on flat ground in 6 minutes collected by an Apple watch worn by subjects for the duration of the study.

Baseline, 12 months
Change in psychosocial distress as measured by the Weight Bias Internalization-Modified (WBIS-M) scale
Tidsramme: Baseline, 12 months

The WBIS-M is a 11-item instrument for measuring the extent to which overweight individuals think of themselves in terms of prevalent negative stereotypes about overweight and overweight individuals. Respondents can express their level of agreement on a 7-point Likert scale ranging from 'strongly disagree' (1) to 'strongly agree' (7). Items 1 and 9 need to be scored reversely. Scores are averaged to create a composite score and higher scores represent greater psychosocial distress.

Baseline, 12 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Kyla Lara-Breitinger, M.D., Mayo Clinic

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

22. april 2024

Primær færdiggørelse (Anslået)

1. maj 2027

Studieafslutning (Anslået)

1. maj 2027

Datoer for studieregistrering

Først indsendt

19. september 2023

Først indsendt, der opfyldte QC-kriterier

19. september 2023

Først opslået (Faktiske)

26. september 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

24. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner